RedHill Biopharma Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$5.4M
Doctors Paid
15,913
Transactions
56,227
2024 Total
$37,325
Payment Breakdown by Category
Research$1.8M (32.6%)
Consulting$1.7M (32.3%)
Food & Beverage$1.0M (18.7%)
Travel$77,696 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 293 | 32.6% |
| Consulting Fee | $1.7M | 210 | 32.3% |
| Food and Beverage | $1.0M | 54,938 | 18.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $799,096 | 536 | 14.9% |
| Travel and Lodging | $77,696 | 239 | 1.4% |
| Grant | $550.00 | 1 | 0.0% |
| Education | $290.89 | 7 | 0.0% |
| Honoraria | $207.86 | 3 | 0.0% |
Payments by Type
General
$3.6M
55,934 transactions
Research
$1.8M
293 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease in Adults With Nodular Bronchiectasis (CleaR-MAC Trial) | $405,171 | 0 | 73 |
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia | $375,096 | 1 | 65 |
| OPAGANIB, A SPHINGOSINE KINASE-2 (SK2) INHIBITOR IN COVID-19 PNEUMONIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A STUDY, IN ADULT SUBJECTS HOSPITALIZED WITH SARS-COV-2 POSITIVE PNEUMONIA | $278,376 | 1 | 58 |
| A PHASE I/IIA STUDY OF ABC294640 ALONE AND IN COMBINATION WITH HYDROXYCHLOROQUINE SULFATE IN THE TREATMENT OF PATIENTS WITH ADVANCED, UNRESECTABLE INTRA-HEPATIC, PERIHILAR AND EXTRA-HEPATIC CHOLANGIOCARCINOMA | $269,992 | 0 | 40 |
| A STUDY OF ABC294640 (YELIVA) ALONE AND IN COMBINATION WITH HYDROXYCHLOROQUINE SULFATE IN TREATMENT OF PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA | $90,041 | 0 | 10 |
| AN OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION RHB-104 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE DESPITE 26 WEEKS OF PARTICIPATION IN THE MAP US RHB-104-01 STUDY | $43,781 | 0 | 16 |
| OPEN LABEL EFFICACY AND SAFETY OF ANTI-MAP (MYCOBACTERIUM AVIUM SSP. PARATUBERCULOSIS) THERAPY IN ADULT CROHN'S DISEASE | $40,616 | 0 | 7 |
| EFFICACY AND SAFETY OF ANTI-MAP THERAPY IN ADULT CROHN'S DISEASE | $11,090 | 0 | 2 |
| A Phase IIA Study of ABC294640 in the Treatment of Patients with Advanced, Unresectable Intra-Hepatic Perihilar and Extra-Hepatic Cholangiocarcinoma | $8,576 | 0 | 14 |
| A RANDOMIZED DOUBLE BLIND ACTIVE COMPARATOR CONTROLLED PHASE III STUDY TO ASSESS THE SAFETY AND EFFICACY OF RHB-105 IN THE TREATMENT OF CONFIRMED HELICOBACTER PYLORI (H. PYLORI) INFECTION | $1,000 | 0 | 1 |
| A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma | $366.80 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Kevin Winthrop, Md, MD | Infectious Disease | Portland, OR | $11,000 | $0 |
| William Chey, Md, MD | Internal Medicine | Ann Arbor, MI | $10,366 | $0 |
| Dr. Michael Epstein, M.d, M.D | Gastroenterology | Annapolis, MD | $10,320 | $0 |
| Dr. Samuel Davidoff, Md, MD | Gastroenterology | Forest Hills, NY | $10,260 | $0 |
| Dr. Anjuli Desai, M.d, M.D | Pain Medicine | Austin, TX | $10,192 | $0 |
| Bradley Connor, Md, MD | Gastroenterology | New York, NY | $9,665 | $0 |
| Dr. Darren Brenner, M.d, M.D | Gastroenterology | Chicago, IL | $9,184 | $0 |
| Dr. Neville Fernandes, M.d, M.D | Gastroenterology | Irving, TX | $8,777 | $0 |
| David Shih, Md, MD | Gastroenterology | Las Vegas, NV | $8,566 | $0 |
| Steven Moss, Md, MD | Gastroenterology | Riverside, RI | $8,553 | $0 |
| Dr. Nimish Vakil, M.d, M.D | Specialist | Summit, WI | $8,397 | $0 |
| Erick Alayo, M.d, M.D | Specialist | Chula Vista, CA | $8,329 | $0 |
| Rashmi Tadiparthi, M.d, M.D | Gastroenterology | Kansas City, KS | $8,165 | $0 |
| Kostas Sideridis, Do, DO | Gastroenterology | Syosset, NY | $8,158 | $0 |
| Dr. Ken Nguyen, M.d, M.D | Gastroenterology | Temple City, CA | $8,104 | $0 |
| Mohammed Barawi, Md, MD | Gastroenterology | St Clair Shores, MI | $8,008 | $0 |
| Dr. Mark Goldberger, M.d, M.D | Infectious Disease | Potomac, MD | $7,758 | $0 |
| John Kao, Md, MD | Internal Medicine | Ann Arbor, MI | $7,701 | $0 |
| Shail Maheshwari, Md, MD | Gastroenterology | Shenandoah, TX | $7,631 | $0 |
| Dr. David Poppers, Md, Phd, MD, PHD | Gastroenterology | New York, NY | $7,604 | $0 |
| Zamir Brelvi, M.d, M.D | Gastroenterology | Newark, NJ | $7,500 | $0 |
| Dr. Ranga Balasekaran, Md, MD | Gastroenterology | Springdale, AR | $7,476 | $0 |
| Dr. Olaitan Adeniji, Md, MD | Gastroenterology | Snellville, GA | $7,317 | $0 |
| Ryan Glidewell, Md, MD | Internal Medicine | Gallatin, TN | $7,280 | $0 |
| Mr. Jeremy Adler, Pa-C, PA-C | Medical | San Diego, CA | $7,082 | $0 |
About RedHill Biopharma Inc.
RedHill Biopharma Inc. has made $5.4M in payments to 15,913 healthcare providers, recorded across 56,227 transactions in the CMS Open Payments database. In 2024, the company paid $37,325. The top product by payment volume is Talicia ($1.3M).
Payments were distributed across 167 medical specialties. The top specialty by payment amount is Internal Medicine ($1.0M to 1,533 doctors).
Payment categories include: Food & Beverage ($1.0M), Consulting ($1.7M), Research ($1.8M), Travel & Lodging ($77,696).
RedHill Biopharma Inc. is associated with 3 products in the CMS Open Payments database.